Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A
Haemophilia · 2023
DOI: 10.1111/hae.14806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Alexandros Arvanitakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Hemophilia A, Joint Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer Health Care.
Abstract (Originalsprache)
Introduction
The timing of prophylaxis and F8 genotype can impact treatment outcomes in adults with severe haemophilia A (HA).
Aim
To investigate how F8 genotype, timing, and type of prophylaxis influence arthropathy, bleeding rates, factor consumption and health‐related quality of life (HRQoL).
Methods
Thirty‐eight patients with severe HA were enrolled. Bleeding events were recorded retrospectively during median 12.5 months. F8 gene variants were classified as null or non‐null. Joint health and HRQoL were assessed with HJHS and EQ‐5D‐5L, respectively.
Results
The median age at prophylaxis start was 1.25 years in the primary prophylaxis group ( N = 15, median age 26 years) and 31.5 years in the secondary group ( N = 22, 45 years), respectively. There were significant differences in the medians of HJHS (4 vs. 20, p < .001), EQ‐5D‐5L index (0.9647 vs. 0.904, p = .022), EQ VAS (87 vs. 75, p = .01) and FVIII consumption (3883 vs. 2737 IU/kg/year, p = .02), between the primary and secondary groups, respectively. Median annualized bleeding rate (ABR) was 0 for both groups. Twenty‐five null and thirteen non‐null F8 gene variants were identified. In the secondary prophylaxis group, lower median FVIII consumption (1926 vs. 3370 IU/kg/year) was shown for non‐null compared to null variants, respectively, with similar ABR and HJHS.
Conclusion
Delayed prophylaxis start with intermediate dose intensity prevents bleeds but at a cost of more arthropathy and reduced HRQoL, compared to higher intensity primary prophylaxis. Non‐null F8 genotype may allow lower factor consumption with similar HJHS and bleeding rates, compared to null genotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, Lund University, Malmö, Sweden.
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
- Department of Hematology, Oslo University Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
ORCID-Profile: Alexandros Arvanitakis, Erik Berntorp, Jan Astermark
Förderung
- Bayer Health Care
Zitieren
APA
Arvanitakis, A., Holme, P. A., Berntorp, E., & Astermark, J. (2023). Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A. Haemophilia. https://doi.org/10.1111/hae.14806
Vancouver
Arvanitakis A, Holme PA, Berntorp E, Astermark J. Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A. Haemophilia. 2023. doi:10.1111/hae.14806
BibTeX
@article{Arvanitakis2023,
author = {Arvanitakis, Alexandros and Holme, Pål Andre and Berntorp, Erik and Astermark, Jan},
title = {Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14806}
}
EUVIMED